Beta-lactam antibiotic offers neuroprotection in a spinal muscular atrophy model by multiple mechanisms

Experimental Neurology

Volumn 229, Issue 2, 2011, Pages 214-225

  Nizzardo, Monica ^a   Nardini, Martina ^a   Ronchi, Dario ^a   Salani, Sabrina ^a   Donadoni, Chiara ^a   Fortunato, Francesco ^a   Colciago, Giorgia ^a   Falcone, Marianna ^a   Simone, Chiara ^a   Riboldi, Giulietta ^a   Govoni, Alessandra ^a   Bresolin, Nereo ^a,b   Comi, Giacomo P ^a   Corti, Stefania ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b SCIENTIFIC INSTITUTE   (Italy)

Author keywords

Ceftriaxone; Pharmacological treatment; Spinal muscular atrophy

Indexed keywords

CEFTRIAXONE; SURVIVAL MOTOR NEURON PROTEIN; TRANSCRIPTION FACTOR NRF2; VESICULAR GLUTAMATE TRANSPORTER 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA MODIFICATION; DRUG EFFECT; DRUG MECHANISM; GENE EXPRESSION PROFILING; MOUSE; NEUROMUSCULAR SYNAPSE; NEUROPROTECTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; RNA METABOLISM; SPINAL MUSCULAR ATROPHY; SURVIVAL; WILD TYPE;

ANALYSIS OF VARIANCE; ANIMALS; ANTI-BACTERIAL AGENTS; BLOTTING, WESTERN; CEFTRIAXONE; CELL COUNT; DISEASE MODELS, ANIMAL; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MICE; MICE, TRANSGENIC; MOTOR NEURONS; MUSCLE, SKELETAL; MUSCULAR ATROPHY, SPINAL; NEUROPROTECTIVE AGENTS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMN COMPLEX PROTEINS; SPINAL CORD; TREATMENT OUTCOME;

EID: 79956158030     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2011.01.017     Document Type: Article

References (56)

1. Andreassi C., Angelozzi C., Tiziano F.D., Vitali T., De Vincenzi E., Boninsegna A., Villanova M., Bertini E., Pini A., Neri G., Brahe C. Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur. J. Hum. Genet. 2004, 12:59-65.
2. Avila A.M., Burnett B.G., Taye A.A., Gabanella F., Knight M.A., Hartenstein P., Cizman Z., Di Prospero N.A., Pellizzoni L., Fischbeck K.H., Sumner C.J. Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J. Clin. Invest. 2007, 117:659-671.
3. Azzouz M., Le T., Ralph G.S., Walmsley L., Monani U.R., Lee D.C., Wilkes F., Mitrophanous K.A., Kingsman S.M., Burghes A.H., Mazarakis N.D. Lentivector-mediated SMN replacement in a mouse model of spinal muscular atrophy. J. Clin. Invest. 2004, 114:1726-1731.
4. Balabanian S., Gendron N.H., MacKenzie A.E. Histologic and transcriptional assessment of a mild SMA model. Neurol. Res. 2007, 29:413-424.
5. Bose J.K., Wang I.F., Hung L., Tarn W.Y., Shen C.K. TDP-43 overexpression enhances exon 7 inclusion during the survival of motor neuron pre-mRNA splicing. J. Biol. Chem. 2008, 283:28852-28859.
6. Bowerman M., Anderson C.L., Beauvais A., Boyl P.P., Witke W., Kothary R. SMN, profilin IIa and plastin 3: a link between the deregulation of actin dynamics and SMA pathogenesis. Mol. Cell. Neurosci. 2009, 42:66-74.
7. Bretscher A. Fimbrin is a cytoskeletal protein that crosslinks F-actin in vitro. Proc. Natl Acad. Sci. 1981, 78:6849-6853.
8. Brichta L., Hofmann Y., Hahnen E., Siebzehnrubl F.A., Raschke H., Blumcke I., Eyupoglu I.Y., Wirth B. Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum. Mol. Genet. 2003, 12:2481-2489.
9. Burghes A.H. When is a deletion not a deletion? When it is converted. Am. J. Hum. Genet. 1997, 61:9-15.
10. Burghes A.H., Beattie C.E. Spinal muscular atrophy: why do low levels of survival motor neuron protein make motor neurons sick?. Nat. Rev. Neurosci. 2009, 10:597-609.
11. Butchbach M.E.R., Burghes A.H.M. Perspectives on models of spinal muscular atrophy for drug discovery. Drug Discov. Today Dis. Models 2004, 1:151-156.
12. Butchbach M.E., Edwards J.D., Burghes A.H. Abnormal motor phenotype in the SMNDelta7 mouse model of spinal muscular atrophy. Neurobiol. Dis. 2007, 27:207-219.
13. Corti S., Nizzardo M., Nardini M., Donadoni C., Salani S., Ronchi D., Saladino F., Bordoni A., Fortunato F., Del Bo R., Papadimitriou D., Locatelli F., Menozzi G., Strazzer S., Bresolin N., Comi G.P. Neural stem cell transplantation can ameliorate the phenotype of a mouse model of spinal muscular atrophy. J. Clin. Invest. 2008, 118:3316-3330.
14. Corti S., Nizzardo M., Nardini M., Donadoni C., Salani S., Del Bo R., Papadimitriou D., Locatelli F., Mezzina N., Gianni F., Bresolin N., Comi G.P. Motoneuron transplantation rescues the phenotype of SMARD1 (spinal muscular atrophy with respiratory distress type 1). J. Neurosci. 2009, 29:1761-1771.
15. DiDonato C.J., Chen X.N., Noya D., Korenberg J.R., Nadeau J.H., Simard L.R. Cloning, characterization, and copy number of the murine survival motor neuron gene: homolog of the spinal muscular atrophy-determining gene. Genome Res. 1997, 7:339-352.
16. El-Khodor B.F., Edgar N., Chen A., Winberg M.L., Joyce C., Brunner D., Suárez-Fariñas M., Heyes M.P. Identification of a battery of tests for drug candidate evaluation in the SMNDelta7 neonate model of spinal muscular atrophy. Exp. Neurol. 2008, 212:29-43.
17. Foust K.D., et al. Intravascular AAV9 preferentially targets neonatal neurons and adult astrocytes. Nat. Biotechnol. 2009, 27(1):59-65.
18. Gabanella F., Butchbach M.E., Saieva L., Carissimi C., Burghes A.H., Pellizzoni L. Ribonucleoprotein assembly defects correlate with spinal muscular atrophy severity and preferentially affect a subset of spliceosomal snRNPs. PLoS ONE 2007, 2:921.
19. Goodman L.S., Gilman A. The Pharmacological Basis of Therapeutics 2001, McGraw-Hill Medical Pub. Division, New York.
20. Greensmith L., Vrbová G. Possible strategies for treatment of SMA patients: a neurobiologist's view. Neuromuscul. Disord. 1995, 5(5):359-369.
21. Grondard C., Biondi O., Armand A.S., Lécolle S., Della Gaspera B., Pariset C., Li H., Gallien C.L., Vidal P.P., Chanoine C., Charbonnier F. Regular exercise prolongs survival in a type 2 spinal muscular atrophy model mouse. J. Neurosci. 2005, 25:7615-7622.
22. Kernochan L.E., Russo M.L., Woodling N.S., Huynh T.N., Avila A.M., Fischbeck K.H., Sumner C.J. The role of histone acetylation in SMN gene expression. Hum. Mol. Genet. 2005, 14:1171-1182.
23. Kirby J., Halligan E., Baptista M.J., Allen S., Heath P.R., Holden H., Barber S.C., Loynes C.A., Wood-Allum C.A., Lunec J., Shaw P.J. Mutant SOD1 alters the motor neuronal transcriptome: implications for familial ALS. Brain 2005, 128:1686-1706.
24. Kwiatkowski T.J., Bosco D.A., Leclerc A.L., Tamrazian E., Vanderburg C.R., Russ C., Davis A., Gilchrist J., Kasarskis E.J., Munsat T., Valdmanis P., Rouleau G.A., Hosler B.A., Cortelli P., de Jong P.J., Yoshinaga Y., Haines J.L., Pericak-Vance M.A., Yan J., Ticozzi N., et al. Mutations in the FUS/TLS gene on chromosome 16 cause familial amyotrophic lateral sclerosis. Science 2009, 323:1205-1208.
25. Le T.T., Pham L.T., Butchbach M.E., Zhang H.L., Monani U.R., Coovert D.D., Gavrilina T.O., Xing L., Bassell G.J., Burghes A.H. SMNDelta7, the major product of the centromeric survival motor neuron (SMN2) gene, extends survival in mice with spinal muscular atrophy and associates with full-length SMN. Hum. Mol. Genet. 2005, 14:845-857.
26. Lee S.G., Su Z.Z., Emdad L., Gupta P., Sarkar D., Borjabad A., Volsky D.J., Fisher P.B. Mechanism of ceftriaxone induction of excitatory amino acid transporter-2 expression and glutamate uptake in primary human astrocytes. J. Biol. Chem. 2008, 283:13116-13123.
27. Lefebvre S., Bürglen L., Reboullet S., Clermont O., Burlet P., Viollet L., Benichou B., Cruaud C., Millasseau P., Zeviani M., et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80:155-165.
28. Lefebvre S., Bürglen L., Frézal J., Munnich A., Melki J. The role of the SMN gene in proximal spinal muscular atrophy. Hum. Mol. Genet. 1998, 7:1531-1536.
29. Lewerenz J., Albrecht P., Tien M.L., Henke N., Karumbayaram S., Kornblum H.I., Wiedau-Pazos M., Schubert D., Maher P., Methner A. Induction of Nrf2 and xCT are involved in the action of the neuroprotective antibiotic ceftriaxone in vitro. J. Neurochem. 2009, 111:332-343.
30. Lorson C.L., Hahnen E., Androphy E.J.A., Wirth B. Single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc. Natl Acad. Sci. USA 1999, 96:6307-6311.
31. Lorson C.L., Rindt H., Shababi M. Spinal muscular atrophy: mechanisms and therapeutic strategies. Hum. Mol. Genet. 2010, 19(R1):R111-R118.
32. Minucci S., Pelicci P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6:38-51.
33. Monani U.R., Lorson C.L., Parsons D.W., Prior T.W., Androphy E.J., Burghes A.H., McPherson J.D. A single nucleotide difference that alters splicing patterns distinguishes the SMA gene SMN1 from the copy gene SMN2. Hum. Mol. Genet. 1999, 8:1177-1183.
34. Monani U.R., Sendtner M., Coovert D.D., Parsons D.W., Andreassi C., Le T.T., Jablonka S., Schrank B., Rossol W., Prior T.W., Morris G.E., Burghes A.H. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum. Mol. Genet. 2000, 9:333-339.
35. Nau R., Sörgel F., Eiffert H. Penetration of drugs through the blood-cerebrospinal fluid/blood-brain barrier for treatment of central nervous system infections. Clin. Microbiol. Rev. 2010, 23(4):858-883.
36. Olaso R., Joshi V., Fernandez J., Roblot N., Courageot S., Bonnefont J.P., Melki J. Activation of RNA metabolism-related genes in mouse but not human tissues deficient in SMN. Physiol. Genomics 2006, 24:97-104.
37. Oprea G.E., Kröber S., McWhorter M.L., Rossoll W., Müller S., Krawczak M., Bassell G.J., Beattie C.E., Wirth B. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science 2008, 320:524-527.
38. Pellizzoni L., Yong J., Dreyfuss G. Essential role for the SMN complex in the specificity of snRNP assembly. Science 2002, 298:1775-1779.
39. Rak K., Lechner B.D., Schneider C., Drexl H., Sendtner M., Jablonka S. Valproic acid blocks excitability in SMA type I mouse motor neurons. Neurobiol. Dis. 2009, 36:477-487.
40. Roberts D.F., Chavez J., Court S.D. The genetic component in child mortality. Arch. Dis. Child. 1970, 45:33-38.
41. Rossoll W., Jablonka S., Andreassi C., Kröning A.K., Karle K., Monani U.R., Sendtner M. Smn, the spinal muscular atrophy-determining gene product, modulates axon growth and localization of beta-actin mRNA in growth cones of motoneurons. J. Cell Biol. 2003, 163:801-812.
42. Rothstein J.D., Jin L., Dykes-Hoberg M., Kuncl R.W. Chronic inhibition of glutamate uptake produces a model of slow neurotoxicity. Proc. Natl Acad. Sci. USA 1993, 90:6591-6595.
43. Rothstein J.D., Patel S., Regan M.R., Haenggeli C., Huang Y.H., Bergles D.E., Jin L., Dykes, Hoberg M., Vidensky S., Chung D.S., Toan S.V., Bruijn L.I., Su Z.Z., Gupta P., Fisher P.B. Beta-lactam antibiotics offer neuroprotection by increasing glutamate transporter expression. Nature 2005, 433:73-77.
44. Rudnik-Schöneborn S., Goebel H.H., Schlote W., Molaian S., Omran H., Ketelsen U., Korinthenberg R., Wenzel D., Lauffer H., Kreiss-Nachtsheim M., Wirth B., Zerres K. Classical infantile spinal muscular atrophy with SMN deficiency causes sensory neuronopathy. Neurology 2003, 60:983-987.
45. Russman B.S., Iannaccone S.T., Samaha F.J. A phase 1 trial of riluzole in spinal muscular atrophy. Arch. Neurol. 2003, 60(11):1601-1603.
46. Schrank B., Götz R., Gunnersen J.M., Ure J.M., Toyka K.V., Smith A.G., Sendtner M. Inactivation of the survival motor neuron gene, a candidate gene for human spinal muscular atrophy, leads to massive cell death in early mouse embryos. Proc. Natl Acad. Sci. USA 1997, 94(18):9920-9925.
47. Sumner C.J., Huynh T.N., Markowitz J.A., Perhac J.S., Hill B., Coovert D.D., Schussler K., Chen X., Jarecki J., Burghes A.H., Taylor J.P., Fischbeck K.H. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann. Neurol. 2003, 54:647-654.
48. Tsai M.S., Chiu Y.T., Wang S.H., Hsieh-Li H.M., Lian W.C., Li H. Abolishing Bax-dependent apoptosis shows beneficial effects on spinal muscular atrophy model mice. Mol. Ther. 2006, 13:1149-1155.
49. Vance C., Rogelj B., Hortobágyi T., De Vos K.J., Nishimura A.L., Sreedharan J., Hu X., Smith B., Ruddy D., Wright P., Ganesalingam J., Williams K.L., Tripathi V., Al-Saraj S., Al-Chalabi A., Leigh P.N., Blair I.P., Nicholson G., de Belleroche J., Gallo J.M., Miller C.C., et al. Mutations in FUS, an RNA processing protein, cause familial amyotrophic lateral sclerosis type 6. Science 2009, 323:208-211.
50. Vargas M.R., Johnson D.A., Sirkis D.W., Messing A., Johnson J.A. Nrf2 activation in astrocytes protects against neurodegeneration in mouse models of familial amyotrophic lateral sclerosis. J. Neurosci. 2008, 28:13574-13581.
51. Wan L., Battle D.J., Yong J., Gubitz A.K., Kolb S.J., Wang J., Dreyfuss G. The survival of motor neurons protein determines the capacity for snRNP assembly: biochemical deficiency in spinal muscular atrophy. Mol. Cell. Biol. 2005, 25:5543-5551.
52. Wang I.F., Reddy N.M., Shen C.K. Higher order arrangement of the eukaryotic nuclear bodies. Proc. Natl Acad. Sci. USA 2002, 99:13583-13588.
53. Wirth B., Brichta L., Schrank B., Lochmüller H., Blick S., Baasner A., Heller R. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum. Genet. 2006, 119:422-428.
54. Yong J., Wan L., Dreyfuss G. Why do cells need an assembly machine for RNA-protein complexes?. Trends Cell Biol. 2004, 14:226-232.
55. Zhang H., Xing L., Rossoll W., Wichterle H., Singer R.H., Bassell G.J. Multiprotein complexes of the survival of motor neuron protein SMN with Gemins traffic to neuronal processes and growth cones of motor neurons. J. Neurosci. 2006, 26:8622-8632.
56. Zhang Z., Lotti F., Dittmar K., Younis I., Wan L., Kasim M., Dreyfuss G. SMN deficiency causes tissue-specific perturbations in the repertoire of snRNAs and widespread defects in splicing. Cell 2008, 133:585-600.